期刊文献+

粪钙卫蛋白在溃疡性结肠炎活动性分级评价中的临床意义 被引量:5

Value of Fecal Calprotectin in Activity Evaluation of Ulcerative Colitis
原文传递
导出
摘要 目的探讨粪钙卫蛋白在溃疡性结肠炎(UC)活动性评价中的临床意义。方法收集2007年9月至2009年12月期间中国医科大学附属第四医院肛肠外科确诊为UC的患者63例及结肠镜检查结果正常但存在相应消化道症状的患者30例,检测并比较其粪钙卫蛋白、红细胞沉降率及C反应蛋白水平。结果活动期Ⅰ、Ⅱ及Ⅲ级组的粪钙卫蛋白和C反应蛋白水平均高于对照组和缓解组(P<0.05),且随活动期级别增高,粪钙卫蛋白的水平逐渐增高(P<0.05);活动期Ⅱ级及Ⅲ级组的C反应蛋白水平均高于Ⅰ级组(P<0.05),但前两者比较差异无统计学意义(P>0.05);5组红细胞沉降率比较差异无统计学意义(P>0.05)。UC活动组的粪钙卫蛋白水平(rs=0.807,P<0.01)、C反应蛋白水平(rs=0.651,P<0.01)和红细胞沉降率(rs=0.371,P<0.05)均与结肠镜下分级相关。结论粪钙卫蛋白可用于评价UC的活动性。由于其检测方法简单、无创、方便及依从性好,具有一定的临床意义。 Objective To explore the value of fecal calprotectin(FCP)in the activity evaluation for ulcerative colitis(UC).Methods Sixty three patients with UC(UC group)and 30 patients with gastrointestinal symptoms but without abnormal results of colonoscopy(control group),who were treated in The Forth Affiliated Hospital of China Medical University between Sep.2007 to Dec.2009 were enrolled to examine the FCP,C-creative protein(CRP),and erythrocyte sedimentation rate(ESR).Then comparison between UC group and control group was performed.Results Levels of FCP and CRP in active grade Ⅰ,Ⅱ,and Ⅲ group were all significantly higher than those of control group and inactive UC group(P〈0.05),with the increase of active grade of UC,the level of FCP gradually increased(P〈0.05).The levels of CRP in active grade Ⅱ and Ⅲ group were all significantly higher than those of grade Ⅰ group(P〈0.05),but didn’t differed between active grade Ⅱ and Ⅲ group(P〈0.05).There were no significant difference among 5 groups on ESR(P〈0.05).Levels of FCP(rs=0.807,P〈0.01),CRP(rs=0.651,P〈0.01),and ESR(rs=0.371,P〈0.05) in active grade group were significantly related to histological grade under colonoscopy.Conclusion FCP examination is simple,inexpensive,repeatable,and noninvasive,and FCP can be used as an marker of activity evaluation in UC.
出处 《中国普外基础与临床杂志》 CAS 2013年第6期648-651,共4页 Chinese Journal of Bases and Clinics In General Surgery
关键词 溃疡性结肠炎 粪钙卫蛋白 C反应蛋白 红细胞沉降率 活动性 Ulcerative colitis Fecal calprotectin C-reactive protein Erythrocyte sedimentation rate Activity
  • 相关文献

参考文献25

  • 1宋璐,夏冰.溃疡性结肠炎发病机制及其诊断[J].中国实用内科杂志,2010,30(11):1056-1058. 被引量:31
  • 2Masoodi I, Tijjani BM, Wani H, et al. Biomarkers in the manag- ement of ulcerative colitis: a brief review [J]. Ger Med Sci, 2011, 9: Doe03.
  • 3中国炎症性肠病诊断治疗规范的共识意见[J].中华内科杂志,2008,47(1):73-79. 被引量:382
  • 4Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial [J]. Br BMJ J, 1955, 2(4947): 1041-1048.
  • 5Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases [J]. Gastroenterology, 2011, 140(6): 1785-1794.
  • 6Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells [ J ]. Bull Eur Physiopathol Respir, 1980, 16 Suppl: 273-282.
  • 7Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monoeytes [J]. Gut, 1994, 35(5): 669-674.
  • 8Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granu- locyte marker protein [J]. Digestion, 1997, 58(2): 176-180.
  • 9Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease [J]. Dig Liver Dis, 2009, 41(1): 56-66.
  • 10沈姞,李俊霞,王化虹,谢鹏雁,刘新光.粪便钙卫蛋白对溃疡性结肠炎的诊断及预测复发的价值[J].肠外与肠内营养,2011,18(5):272-276. 被引量:13

二级参考文献62

  • 1刘文斌,吕愈敏,金珠,杨雪玲.钙卫蛋白在溃疡性结肠炎患者结肠黏膜及粪便中的表达及临床意义[J].北京大学学报(医学版),2005,37(2):179-182. 被引量:17
  • 2Fagerhol MK.Calprotectin,a faecal marker of organic gastrointestinal abnormality.Lancet,2000,356 (9244):1783-1784.
  • 3陈灏珠主编.溃疡性结肠炎.实用内科学,北京:人民卫生出版社,2005:1914-1918.
  • 4Vermeire S,Van Assche G,Rutgeerts P.Laboratory markers In IBD:Useful,Magic,or unnecessary toys? Gut,2006,55 (3):426-431.
  • 5Canani RB,Terrin G,Rapacciuolo L,et al.Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.Digestive and Liver Disease,2008,40(7):547-553.
  • 6Roseth AG,Schmidt PN,Fagerhol MK.Correlation between faecal excretion of Indium-111 labelled granulocytes and calprotectin,a gran-ulocyte marker protein,in patients with inflammatory bowel disease.Scand J Gastroentero1,1999,34 (1):50-54.
  • 7Summerton CB,Longlands MG,Wiener K,et al.Faecal calprotectin:a marker of inflammation throughout the intestinal tract.Eur J Gastroenterol Hepatol,2002,14 (8):841-845.
  • 8Hanai H,Takeuchi K,lida T,et al.Relationship between fecal calprotectin,intestinal inflammation,and peripheral blood neutrophils in patients with active ulcerative colitis.Dig Dis Sci,2004,49(9):1438-1443.
  • 9Roseth AG,Aadland E,Jahnsen J,et al.Assessment of disease activity in ulcerative colitis by faecal calprotectin,a novel granulocyte marker protein.Digestion,1997,58 (2):176-180.
  • 10Costa F,Mumolo MG,Ceccarelli L,et al.Calprotectin is a strong predictive marker of relapse in ulcerative colitis than in Crohn's disease.Gut,2005,54 (3):364-368.

共引文献474

同被引文献53

  • 1戴军,刘文忠,赵永平,胡运彪,戈之铮.粪乳铁蛋白与炎症性肠病的相关性研究[J].中华消化杂志,2006,26(6):393-395. 被引量:8
  • 2欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495. 被引量:751
  • 3Huang VW, Prosser C, Kroeker KI, et al. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical De- cision-making for IBD Outpatients on Maintenance Infliximab Therapy[J]. Inflannn Bowel Dis,2015,21 (6) :1 359 -1 367.
  • 4Caviglia GP, Pantaleoni S, Touscoz GA, et al. Fecal calprotec- tin is an effective diagnostic tool that differentiates inflamma- tory from functional intestinal disorders [ J ]. Scand J Gastro- enterol,2014,49(12) :1 419 - 1 424.
  • 5Gionchetti P, D'Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropi- onate or mesalamine:a single-blind randomized controlled tri- al[ J]. J Clin Gastroenterol,2005,39(4) :291 -297.
  • 6Truelove SC, Witts LJ. Cortisone in ulcerative colitis ;final re- port on a therapeutic trial [ J ]. Br Med J, 1955,2 ( 4 947 ) : 1 041 -1 048.
  • 7Cerrillo E ,Behren B ,Pous S ,et al. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance En- terography and a Pathology Score [ J ]. Inflamm Bowel Dis, 2015,21(7) :1 572-1 579.
  • 8Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish or- ganic from nonorganic intestinal disease [ J ]. Gastroenterolo- gy ,2002,123 (2) :450 - 460.
  • 9Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quies- cent ulcerative colitis during maintenance therapy [ J ]. Int J Colorectal Dis,2014,29(4) :485 -491.
  • 10Aksyonov A, Mitrokhin VM, Mladenov MI. Effects of interleu- kin-2 on bioelectric activity of rat atrial myocardium under normal conditions and during gradual stretching[ J]. Immunol Lett,2015,167( 1 ) :23 -28.

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部